Plus Therapeutics announced that its REYOBIQ Phase 1 dose‑escalation abstract has been accepted for a poster‑spotlight presentation with an oral component at the San Antonio Breast Cancer Symposium (SABCS). The abstract will be presented on Friday, December 12, 2025, from 7:39 am to 7:42 am Central Standard Time.
The study evaluates REYOBIQ, a targeted radiotherapeutic designed to treat leptomeningeal metastases, a rare and aggressive complication of advanced cancer. The abstract summarizes early safety and preliminary efficacy data from the dose‑escalation cohort, providing the first peer‑reviewed evidence of the drug’s activity in this patient population.
For a company still in the early clinical phase, acceptance at SABCS is a significant milestone. It grants visibility to a large oncology audience, opens doors for potential collaborations and payer discussions, and can accelerate regulatory engagement by demonstrating tangible clinical progress. Investors view such milestones as a positive signal that the pipeline is moving forward and that the company is building a foundation for future approvals and revenue streams.
Financially, Plus Therapeutics reported a Q3 2025 net loss of $4.42 million, up from $2.87 million a year earlier, and revenue of $1.40 million, below the $1.50 million consensus estimate. The company’s cash and investments stood at $3.6 million at year‑end 2024, down from $8.6 million in 2023, but a $15 million equity financing in March 2025 and a $17.6 million grant from the Cancer Prevention & Research Institute of Texas have extended the cash runway into mid‑2026.
CEO Marc H. Hedrick emphasized the strategic importance of the abstract, describing 2025 as “transformational” with the launch of CNSide, the company’s molecular diagnostic service. Hedrick also noted that a single 44‑millicurie dose of REYOBIQ could warrant FDA approval for leptomeningeal metastases, underscoring the potential for a rapid regulatory pathway if the data continue to be favorable.
The company has also regained compliance with Nasdaq’s listing requirements, having secured an extension to meet the $1.00 minimum bid price and the market‑value and equity thresholds. This compliance, combined with the conference milestone, reinforces investor confidence in the company’s ability to sustain operations and pursue its clinical agenda.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.